---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058230"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:50:44.907966+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MindMed Q3 net loss $17.9M; cash $117.7M; Phase 2b GAD topline expected Q4 2023

## Summary
- Cash and cash equivalents $117.7M at Sept 30, 2023; expected to fund operations into 2026.
- Net loss $17.9M in Q3 2023 vs $16.5M in Q3 2022; R&D expenses rose to $13.2M from $7.8M.
- Phase 2b study of MM-120 in GAD (198 participants) topline results expected in Q4 2023.
- Phase 2a proof-of-concept study of MM-120 in ADHD (53 participants) topline data expected Q1 2024.
- Initiation of Phase 1 study of MM-402 for ASD expected in Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-058230
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/0000950170-23-058230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/mnmd-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058230
- JSON: https://secwatch.observer/filing/0000950170-23-058230.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058230.txt

## Key facts
- Earnings Releases
  Definium Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023, was $17.9 million.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss for the quarter ended September 30, 2023, was $17.9 million
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023, was $17.9 million, compared to $16.5 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/0000950170-23-058230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.